Triglycidylisocyanurate(TGIC;Teroxirone)是一种具有抗血管生成和抗肿瘤活性的三氮烯三环氧化合物。Triglycidylisocyanurate通过p53的激活抑制非小细胞肺癌细胞的生长。Triglycidylisocyanurate诱导细胞凋亡(apoptosis)。Triglycidylisocyanurate可用于癌症研究。
货号:ajcx31610
CAS:2451-62-9
分子式:C12H15N3O6
分子量：297.26
溶解度:DMSO: 50 mg/mL (168.20 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research[1][2].

Triglycidyl isocyanurate (0-30 μM; 48?hours) reduces the growth of spheroids of human non-small-cell-lung cancer cells in culture, it leads to a gradual reduction in size for tumorspheres of A549, H460 and H1299 cells[1].Triglycidyl isocyanurate (0-30 μM; 48?hours) inhibits expression of akt1/2/3 and phosphorylated Aktser473/474/472 of A549, H460 and H1299 tumorspheres, however, the cleavage of PARP and procaspase-3 plus the emergent active caspase-3 fragment are only visible in H460 and A549 tumorspheres[1]. Cell Viability Assay[1] Cell Line: A549, H460 and H1299 cells

Triglycidyl isocyanurate (subcutaneous injection; 1.8 and 3.6 mg/kg; every 2-3 days for total seven times; 30 days) suppresses the growth of xenograft tumors and has no effects on weight in nude mice[2]. Animal Model: Female nu/nu mice with Huh7 cells subcutaneously injected into the dorsal area[2]

[1]. Yu-Ling Ni, et al. Teroxirone motivates apoptotic death in tumorspheres of human lung cancer cells. Chem Biol Interact. 2018 Aug 1;291:137-143 [2]. Seung-Hun Kim, et al. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells.Biomed Pharmacother. 2018 Mar;99:997-1008